生物科技公司Maravai LifeSciences Holdings, Inc.(MRVI.O)今日盘前大跌近40%,原因是该公司下调了2024年全年营收预期,同时第三季度业绩也低于预期。
Maravai在最新的财报中将2024年全年营收预期从之前预计的2.65亿至2.85亿美元下调至2.55亿至2.65亿美元。公司第三季度营收为6520万美元,低于分析师预期的6756万美元。业绩疲软和预期下调令投资者失望。
此外,Maravai还宣布计划收购意大利生物科技公司Officinae Bio的DNA和RNA业务。这一收购计划可能会在短期内增加公司的成本和财务压力,影响股价表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.